In 2023, Capital Blue Cross members will be able to use their insurance cards at Mark Cuban Cost Plus Drugs. This is the first time the online pharmacy will accept insurance.
Capital Blue Cross in Harrisburg, Pa., will become the first health plan to collaborate with the Mark Cuban Cost Plus Drug Company. In 2023, Capital Blue Cross members will be able to use their insurance cards at Cost Plus Drugs. The insurer serves a 21-county region in Central Pennsylvania and the Lehigh Valley by offering health insurance products, services and technology solutions.
This agreement with marks the first time the Cost Plus Drug will accept insurance. Mark Cuban Cost Plus Drug Company launched in January 2022 offering cash-paying customers access to lower-cost generic medications. Medications are priced at cost with a 15% markup. The direct-to-consumer pharmacy now carries almost 1,000 medications.
“Working with a like-minded organization like Capital gives us more momentum to help people get the medications they need at costs they can afford,” Alex Oshmyansky, M.D., Ph.D., CEO of Mark Cuban Cost Plus Drug Company said in a press release.
Related: First PBM Integrates with Mark Cuban Cost Plus Drug Company
This announcement follows one last month in which Rightway became the first PBM to offer access to the generic drugs offered by Cost Plus Drug through its mobile app. Rightway’s pharmacists will identify members, such as those with chronic conditions, who may benefit from the service with Cost Plus Drugs and help them transfer their medications if they choose to do so.
FDA Issues Complete Response Letter for Pz-Cel to Treat Epidermolysis Bullosa
April 22nd 2024Prademagene zamikeracel is a cell therapy designed to incorporate the functional collagen-producing COL7A1 gene into a patient’s own skin cells. The FDA is asking for additional information on manufacturing practices.
Read More
FDA Approves Stelara Biosimilar, Selarsdi
April 18th 2024Alvotech’s Selarsdi (ustekinumab-aekn), a biosimilar referencing Stelara (ustekinumab), gained FDA approval, making it the second ustekinumab biosimilar and second for the company to be given the green light for the American market.
Read More